• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form D filed by Longeveron Inc.

    3/25/26 10:13:59 AM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LGVN alert in real time by email
    Form D
    FORM D
    Notice of Exempt Offering of Securities

    UNITED STATES SECURITIES
    AND EXCHANGE COMMISSION
    Washington, D.C.

    OMB APPROVAL
    OMB Number: 3235-0076
    Estimated Average burden hours per response: 4.0
    1. Issuer's Identity
    CIK (Filer ID Number)Previous Name(s)Checkbox not checkedNoneEntity Type
    0001721484
    LONGEVERON LLC
    Radio button checkedCorporation
    Radio button not checked Limited Partnership
    Radio button not checked Limited Liability Company
    Radio button not checked General Partnership
    Radio button not checked Business Trust
    Radio button not checkedOther 
    Name of Issuer
     Longeveron Inc.
    Jurisdiction of Incorporation/Organization
    DELAWARE 
    Year of Incorporation/Organization
    Radio button checkedOver Five Years Ago
    Radio button not checkedWithin Last Five Years (Specify Year)
     
    Radio button not checkedYet to Be Formed
     
      
      
     
    2. Principal Place of Business and Contact Information
    Name of Issuer
     Longeveron Inc.
    Street Address 1Street Address 2
     1951 NW 7TH AVENUE
     SUITE 520
    CityState/Province/CountryZIP/Postal CodePhone No. of Issuer
     MIAMI
     FLORIDA
     
     33136
     305-909-0840 




    3. Related Persons

    Last NameFirst NameMiddle Name
    Willard
    Stephen
    H.
    Street Address 1Street Address 2
     1951 NW 7th Avenue 
     Suite 520
    CityState/Province/CountryZIP/Postal Code
     Miami
     FLORIDA
     33136
     
    Relationship:Checkbox checkedExecutive OfficerCheckbox not checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
     



    Last NameFirst NameMiddle Name
    Hare
    Joshua
    M.
    Street Address 1Street Address 2
     1951 NW 7th Avenue 
     Suite 520
    CityState/Province/CountryZIP/Postal Code
     Miami
     FLORIDA
     33136
     
    Relationship:Checkbox checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
     



    Last NameFirst NameMiddle Name
    Locklear
    Lisa
    A.
    Street Address 1Street Address 2
     1951 NW 7th Avenue 
     Suite 520
    CityState/Province/CountryZIP/Postal Code
     Miami
     FLORIDA
     33136
     
    Relationship:Checkbox checkedExecutive OfficerCheckbox not checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
     



    Last NameFirst NameMiddle Name
    Agafonova
    Nataliya
    Street Address 1Street Address 2
     1951 NW 7th Avenue 
     Suite 520
    CityState/Province/CountryZIP/Postal Code
     Miami
     FLORIDA
     33136
     
    Relationship:Checkbox checkedExecutive OfficerCheckbox not checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
     



    Last NameFirst NameMiddle Name
    Lehr
    Paul
    Street Address 1Street Address 2
     1951 NW 7th Avenue 
     Suite 520
    CityState/Province/CountryZIP/Postal Code
     Miami
     FLORIDA
     33136
     
    Relationship:Checkbox checkedExecutive OfficerCheckbox not checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
     



    Last NameFirst NameMiddle Name
    Blass
    Devin
    Street Address 1Street Address 2
     1951 NW 7th Avenue 
     Suite 520
    CityState/Province/CountryZIP/Postal Code
     Miami
     FLORIDA
     33136
     
    Relationship:Checkbox checkedExecutive OfficerCheckbox not checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
     



    Last NameFirst NameMiddle Name
    Soffer
    Rock
    Street Address 1Street Address 2
     1951 NW 7th Avenue 
     Suite 520
    CityState/Province/CountryZIP/Postal Code
     Miami
     FLORIDA
     33136
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
     



    Last NameFirst NameMiddle Name
    Ungaro
    Ursula
    Street Address 1Street Address 2
     1951 NW 7th Avenue 
     Suite 520
    CityState/Province/CountryZIP/Postal Code
     Miami
     FLORIDA
     33136
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
     



    Last NameFirst NameMiddle Name
    Hajjar
    Roger
    Joseph
    Street Address 1Street Address 2
     1951 NW 7th Avenue 
     Suite 520
    CityState/Province/CountryZIP/Postal Code
     Miami
     FLORIDA
     33136
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
     



    Last NameFirst NameMiddle Name
    Paletta, Jr.
    George
    Street Address 1Street Address 2
     1951 NW 7th Avenue 
     Suite 520
    CityState/Province/CountryZIP/Postal Code
     Miami
     FLORIDA
     33136
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
     





    4. Industry Group
     Radio button not checkedAgriculture
    Banking & Financial Services
     Radio button not checked Commercial Banking
     Radio button not checked Insurance
     Radio button not checkedInvesting
     Radio button not checked Investment Banking
     Radio button not checked Pooled Investment Fund

     Radio button not checkedOther Banking & Financial Services
    Radio button not checked Business Services
    Energy
     Radio button not checked Coal Mining
     Radio button not checked Electric Utilities
     Radio button not checked Energy Conservation
     Radio button not checked Environmental Services
     Radio button not checked Oil & Gas
     Radio button not checked Other Energy
    Health Care
     Radio button checked Biotechnology
     Radio button not checked Health Insurance
     Radio button not checked Hospitals & Physicians
     Radio button not checked Pharmaceuticals
     Radio button not checked Other Health Care
       
       
       
      
    Radio button not checked Manufacturing
    Real Estate
     Radio button not checkedCommercial
     Radio button not checkedConstruction
     Radio button not checkedREITS & Finance
     Radio button not checkedResidential
    Radio button not checkedOther Real Estate
    Radio button not checked Retailing
    Radio button not checkedRestaurants
    Technology
    Radio button not checked Computers
    Radio button not checked Telecommunications
    Radio button not checked Other Technology
    Travel
    Radio button not checked Airlines & Airports
    Radio button not checked Lodging & Conventions
    Radio button not checked Tourism & Travel Services
    Radio button not checked Other Travel
    Radio button not checkedOther

      
       
    5. Issuer Size
    Revenue RangeAggregate Net Asset Value Range
    Radio button not checkedNo RevenuesRadio button not checked No Aggregate Net Asset Value
    Radio button not checked $1 - $1,000,000Radio button not checked$1 - $5,000,000
    Radio button not checked $1,000,001 - $5,000,000Radio button not checked $5,000,001 - $25,000,000
    Radio button not checked$5,000,001 - $25,000,000Radio button not checked $25,000,001 - $50,000,000
    Radio button not checked$25,000,001 - $100,000,000Radio button not checked $50,000,001 - $100,000,000
    Radio button not checked Over $100,000,000Radio button not checked Over $100,000,000
    Radio button checked Decline to Disclose Radio button not checkedDecline to Disclose
    Radio button not checked Not ApplicableRadio button not checked Not Applicable

     
    6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)
    Checkbox not checkedRule 504(b)(1) (not (i), (ii)
    or (iii))
    Checkbox checkedRule 506(b)      
    Checkbox not checkedRule 504 (b)(1)(i) Checkbox not checkedRule 506(c)
    Checkbox not checkedRule 504 (b)(1)(ii) Checkbox not checkedSecurities Act Section 4(a)(5)
    Checkbox not checkedRule 504 (b)(1)(iii)Checkbox not checkedInvestment Company Act Section 3(c)
     
     

    7. Type of Filing
    Checkbox checked New Notice Date of First Sale 
    2026-03-11
    Checkbox not checked First Sale Yet to Occur
    Checkbox not checked Amendment


     
     
    8. Duration of Offering
    Does the Issuer intend this offering to last more than one year? Radio button not checked Yes Radio button checked No
     
     
    9. Type(s) of Securities Offered (select all that apply)
    Checkbox not checkedPooled Investment Fund InterestsCheckbox checkedEquity
    Checkbox not checkedTenant-in-Common Securities Checkbox not checkedDebt
    Checkbox not checkedMineral Property SecuritiesCheckbox checkedOption, Warrant or Other Right to Acquire Another Security
    Checkbox checkedSecurity to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire SecurityCheckbox checkedOther (describe)
    An interest in 50% of proceeds received (after deducting fees) from the potential future sale of a Rare Pediatric Disease Priority Review Voucher, to the extent received from the U.S. FDA in connection with the Company's laromestrocel program for HLHS.
     
     
    10. Business Combination Transaction
    Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? Radio button not checked Yes Radio button checked No
    Clarification of Response (if Necessary)
     
     
     
    11. Minimum Investment
    Minimum investment accepted from any outside investor$
     0
    USD

    12. Sales Compensation
    Recipient Recipient CRD NumberCheckbox not checkedNone
     H.C. Wainwright & Co., LLC
     375
    (Associated) Broker or DealerCheckbox not checkedNone(Associated) Broker or Dealer CRD Number Checkbox not checkedNone
     Charles Worthman
     516096
    Street Address 1      Street Address 2
    430 Park Avenue
    4th Floor
    City State/Province/CountryZIP/Postal Code
     New York
     NEW YORK
     10022
    State(s) of SolicitationCheckbox not checkedAll StatesCheckbox not checkedForeign/Non-US
     
    CALIFORNIA
    COLORADO
    NEW YORK
    TEXAS

    Recipient Recipient CRD NumberCheckbox not checkedNone
     H.C. Wainwright & Co., LLC
     375
    (Associated) Broker or DealerCheckbox not checkedNone(Associated) Broker or Dealer CRD Number Checkbox not checkedNone
     Noam Rubinstein
     4070245
    Street Address 1      Street Address 2
    430 Park Avenue
    4th Floor
    City State/Province/CountryZIP/Postal Code
     New York
     NEW YORK
     10022
    State(s) of SolicitationCheckbox not checkedAll StatesCheckbox not checkedForeign/Non-US
     
    CALIFORNIA
    COLORADO
    NEW YORK
    TEXAS

    Recipient Recipient CRD NumberCheckbox not checkedNone
     H.C. Wainwright & Co., LLC
     375
    (Associated) Broker or DealerCheckbox not checkedNone(Associated) Broker or Dealer CRD Number Checkbox not checkedNone
     Craig Schwabe
     3137679
    Street Address 1      Street Address 2
    430 Park Avenue
    4th Floor
    City State/Province/CountryZIP/Postal Code
     New York
     NEW YORK
     10022
    State(s) of SolicitationCheckbox not checkedAll StatesCheckbox not checkedForeign/Non-US
     
    CALIFORNIA
    COLORADO
    NEW YORK
    TEXAS

    Recipient Recipient CRD NumberCheckbox not checkedNone
     H.C. Wainwright & Co., LLC
     375
    (Associated) Broker or DealerCheckbox not checkedNone(Associated) Broker or Dealer CRD Number Checkbox not checkedNone
     Michael Vasinkevich
     2843810
    Street Address 1      Street Address 2
    430 Park Avenue
    4th Floor
    City State/Province/CountryZIP/Postal Code
     New York
     NEW YORK
     10022
    State(s) of SolicitationCheckbox not checkedAll StatesCheckbox not checkedForeign/Non-US
     
    CALIFORNIA
    COLORADO
    NEW YORK
    TEXAS




    13. Offering and Sales Amounts
     
    Total Offering Amount $
    33515000
    USDCheckbox not checkedIndefinite
    Total Amount Sold $
    15890000
    USD
    Total Remaining to be Sold $
    17625000
    USDCheckbox not checkedIndefinite
    Clarification of Response (if Necessary)
    Total offering amount: purchase price of shares of Class A common stock, Series A Preferred Stock, an interest in future proceeds from a potential future PRV sale, proceeds due to Company assuming cash exercise of all warrants issued to placement agent
     
    14. Investors

    Checkbox not checkedSelect if securities in the offering have been or may be sold to persons who do not qualify as accredited investors,
    Number of such non-accredited investors who already have invested in the offering
       
      Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
    7
     
    15. Sales Commissions & Finders’ Fees Expenses
    Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
    Sales Commissions$
    2224600
    USDCheckbox checkedEstimate
    Finders' Fees$
    0
    USDCheckbox not checkedEstimate
    Clarification of Response (if Necessary)
    At initial closing, placement agent received $1,112,300.01 & warrants to purchase up to 2,019,231 shares of Common Stock exercisable at $0.65 per share, among other items. Contingent upon a second closing, placement agent will receive an identical comp.
     

    16. Use of Proceeds
    Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
     $ 
    0
    USDCheckbox not checkedEstimate
    Clarification of Response (if Necessary)
     

    Signature and Submission
     
    Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.
    Terms of Submission 
     In submitting this notice, each Issuer named above is: 
     
    • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, the information furnished to offerees.
    • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the Issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
    • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).
     
    Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.
    For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.
     
    IssuerSignatureName of SignerTitleDate
    Longeveron Inc./s/ Lisa A. LocklearLisa A. LocklearChief Financial Officer2026-03-25




    Get the next $LGVN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LGVN

    DatePrice TargetRatingAnalyst
    12/6/2024$10.00Buy
    ROTH MKM
    1/5/2022$20.00Buy
    EF Hutton
    More analyst ratings

    $LGVN
    SEC Filings

    View All

    Longeveron Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - Longeveron Inc. (0001721484) (Filer)

    3/25/26 4:00:38 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form D filed by Longeveron Inc.

    D - Longeveron Inc. (0001721484) (Filer)

    3/25/26 10:13:59 AM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Longeveron Inc. filed SEC Form 8-K: Other Events

    8-K - Longeveron Inc. (0001721484) (Filer)

    3/24/26 4:01:06 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LGVN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Longeveron Announces 2025 Full Year Financial Results and Provides Business Update

    On track for third quarter 2026 top-line trial results from anticipated pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indicationELPIS II may serve as foundation for a Biologics License Application (BLA) submission for full approval for HLHS, if results demonstrate sufficient evidence of efficacyClosed a private placement of up to $30 million, with $15 million funded in the initial closing, led by Coastlands Capital with participation from Janus Henderson Investors and other healthcare focused fundsCompany to host conference call and webcast today at 4:30 p.m. ET MIAMI, March 17

    3/17/26 4:05:00 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Longeveron to Report 2025 Full-Year Financial Results and Host Conference Call on March 17, 2026

    MIAMI, March 12, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will report 2025 full year financial results and provide a business update on Tuesday, March 17, 2026 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET. Conference Call and Webcast Details: Conference Call Number:1.877.407.0789Conference ID:13758462  Call meTM Feature:Click HereWebcast:Click Here   An archived replay of the webcast will be available on the "Events & Presentations" sec

    3/12/26 9:00:00 AM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Longeveron Announces Closing of Private Placement of up to $30 Million

    $15 million upfront with a milestone-driven potential additional $15 million related to the Company's anticipated pivotal clinical trial in Hypoplastic Left Heart Syndrome (HLHS) priced at the market under Nasdaq rules Private placement led by Coastlands Capital with participation from Janus Henderson Investors and other healthcare focused fundsInitial proceeds extend cash runway into 4Q26, past the anticipated pivotal Phase 2b ELPIS II clinical trial 3Q26 topline data readout MIAMI, March 11, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions,

    3/11/26 4:05:00 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LGVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH MKM initiated coverage on Longeveron with a new price target

    ROTH MKM initiated coverage of Longeveron with a rating of Buy and set a new price target of $10.00

    12/6/24 7:54:21 AM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EF Hutton initiated coverage on Longeveron with a new price target

    EF Hutton initiated coverage of Longeveron with a rating of Buy and set a new price target of $20.00

    1/5/22 10:22:40 AM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LGVN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Willard Stephen H was granted 400,000 shares and covered exercise/tax liability with 105,533 shares (SEC Form 4)

    4 - Longeveron Inc. (0001721484) (Issuer)

    3/13/26 8:59:13 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Willard Stephen H claimed no ownership of stock in the company (SEC Form 3)

    3 - Longeveron Inc. (0001721484) (Issuer)

    3/13/26 8:58:57 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Locklear Lisa covered exercise/tax liability with 10,250 shares, decreasing direct ownership by 4% to 228,831 units (SEC Form 4)

    4 - Longeveron Inc. (0001721484) (Issuer)

    1/6/26 6:00:19 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LGVN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Baluch Khoso bought 11,766 shares, increasing direct ownership by 29% to 52,516 units (SEC Form 4)

    4 - Longeveron Inc. (0001721484) (Issuer)

    8/13/25 6:00:07 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Locklear Lisa bought 11,766 shares, increasing direct ownership by 5% to 250,964 units (SEC Form 4)

    4 - Longeveron Inc. (0001721484) (Issuer)

    8/13/25 6:00:08 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hare Joshua bought $350,000 worth of shares (148,936 units at $2.35), increasing direct ownership by 31% to 633,280 units (SEC Form 4)

    4 - Longeveron Inc. (0001721484) (Issuer)

    4/12/24 7:00:29 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LGVN
    Financials

    Live finance-specific insights

    View All

    Longeveron Announces 2025 Full Year Financial Results and Provides Business Update

    On track for third quarter 2026 top-line trial results from anticipated pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indicationELPIS II may serve as foundation for a Biologics License Application (BLA) submission for full approval for HLHS, if results demonstrate sufficient evidence of efficacyClosed a private placement of up to $30 million, with $15 million funded in the initial closing, led by Coastlands Capital with participation from Janus Henderson Investors and other healthcare focused fundsCompany to host conference call and webcast today at 4:30 p.m. ET MIAMI, March 17

    3/17/26 4:05:00 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Longeveron to Report 2025 Full-Year Financial Results and Host Conference Call on March 17, 2026

    MIAMI, March 12, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will report 2025 full year financial results and provide a business update on Tuesday, March 17, 2026 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET. Conference Call and Webcast Details: Conference Call Number:1.877.407.0789Conference ID:13758462  Call meTM Feature:Click HereWebcast:Click Here   An archived replay of the webcast will be available on the "Events & Presentations" sec

    3/12/26 9:00:00 AM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Longeveron® to Report Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025

    MIAMI, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will report third quarter 2025 financial results and provide a business update on Tuesday, November 4, 2025 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET. Conference Call and Webcast Details:   Conference Call Number: 1.877.407.0789Conference ID: 13755997   Call me™ Feature: Click HereWebcast: Click Here An archived replay of the webcast will be available on the "Events & Presenta

    10/28/25 9:15:00 AM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LGVN
    Leadership Updates

    Live Leadership Updates

    View All

    Longeveron® Appoints Stephen H. Willard as Chief Executive Officer

    Mr. Willard has a 30+ year track record of leadership across public and private sectors as CEO of multiple biotechnology and pharmaceutical firms, with an impressive history of delivering significant fundraises and strategic collaborationsCorporate focus on delivering top-line results from the pivotal Phase 2b clinical trial in Hypoplastic Left Heart Syndrome (HLHS), anticipated in the third quarter of 2026 Than Powell stepped down as interim CEO; will remain with the Company to support the leadership transition and continue his work in the Company's on-going business development activities MIAMI, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerati

    2/13/26 4:30:00 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    George Paletta, Jr., MD, MBA, Internationally Acclaimed Entrepreneur, Investor and Surgeon, Elected to Longeveron® Board of Directors

    MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that George Paletta, Jr., MD, MBA, has been elected to the Longeveron Board of Directors. Dr. Paletta is a nationally and internationally recognized orthopedic surgeon and the head team doctor for the St. Louis Cardinals. Dr. Paletta is a developer of ambulatory surgical centers (ASCs), and has participated in the selling of two ASCs with deal values totaling almost $1 billion. "I am delighted to welcome George, and his tremendous experience as a physician, inv

    10/1/25 4:05:00 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Longeveron® Appoints Than Powell as Chief Business Officer

    Mr. Powell to oversee Longeveron's partnering and international strategy efforts MIAMI, June 26, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has appointed Than Powell as Chief Business Officer, effective July 7, 2025. In this role, he will lead the Company's overall business strategy, Alzheimer's disease program partnering efforts, and international strategy for the hypoplastic left heart syndrome (HLHS) program. "We are delighted to have Than join Longeveron at this transformational time in the Company's

    6/26/25 9:05:00 AM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LGVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Longeveron Inc.

    SC 13G/A - Longeveron Inc. (0001721484) (Subject)

    11/14/24 4:20:18 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Longeveron Inc.

    SC 13G - Longeveron Inc. (0001721484) (Subject)

    7/26/24 4:18:08 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Longeveron Inc.

    SC 13G - Longeveron Inc. (0001721484) (Subject)

    4/17/24 4:03:33 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care